Clinical evaluation of a single oral dose of human-bovine (UK) reassortant rotavirus vaccines Wa x UK (P1A[8],G6) and Wa x (DS-1 x UK) (P1A[8],G2)

Journal of Medical Virology

Volumn 66, Issue 3, 2002, Pages 407-416

  Eichelberger, Maryna C ^a   Sperber, Ellen ^b   Wagner, Mariam ^a   Hoshino, Yasutaka ^a   Dudas, Robert ^b   Hodgins, Vicki ^b   Marron, Jennifer ^b   Nehring, Pamela ^a   Casey, Roberta ^a   Burns, Barbara ^a   Karron, Ruth ^b   Clements Mann, Mary Lou ^a,b   Kapikian, Albert Z ^a,b  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

Clinical trials; Rotavirus; Vaccine

Indexed keywords

ALANINE AMINOTRANSFERASE; GENE PRODUCT; PLACEBO; PROTEIN VP4; PROTEIN VP7; ROTAVIRUS VACCINE; UNCLASSIFIED DRUG;

ADULT; AMINO ACID SUBSTITUTION; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; IMMUNOGENICITY; INFANT; INFECTION; LIVER FUNCTION; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PRESCHOOL CHILD; RANDOMIZED CONTROLLED TRIAL; ROTAVIRUS; SIDE EFFECT; STRAIN DIFFERENCE; VIRUS GENE; VIRUS INFECTION;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; ANIMALS; ANTIBODIES, VIRAL; ANTIGENS, VIRAL; CAPSID; CAPSID PROTEINS; CATTLE; CELLS, CULTURED; CERCOPITHECUS AETHIOPS; CHILD, PRESCHOOL; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; HUMANS; INFANT; MIDDLE AGED; RECOMBINATION, GENETIC; ROTAVIRUS; ROTAVIRUS INFECTIONS; ROTAVIRUS VACCINES;

BOVINAE; HUMAN ROTAVIRUS A; ROTAVIRUS;

EID: 0036157292     PISSN: 01466615     EISSN: None     Source Type: Journal    
DOI: 10.1002/jmv.2160     Document Type: Article

References (33)

1. Phase I trial of a candidate rotavirus vaccine (RV3) derived from a human neonate
2. Evaluation of WC3 rotavirus vaccine and correlates of protection in healthy infants
3. Efficacy of live, attenuated, human rotavirus vaccine 89-12 in infants: A randomized placebo-controlled trial
4. Rotavirus vaccine for the prevention of rotavirus gastroenteritis among children
5. Intussusception among recipients of rotavirus vaccine: United States, 1998-1999
6. Withdrawal of rotavirus vaccine recommendation
7. WC3 reassortant vaccines in children
8. Safety and immunogenicity of live attenuated human-bovine (UK) reassortant rotavirus vaccines with VP7-specificity for serotypes 1, 2, 3 or 4 in adults, children and infants
9. Safety and immunogenicity of live attenuated quadrivalent human-bovine (UK) reassortant rotavirus vaccine administered with childhood vaccines to infants
10. Prevention of rotavirus disease: Guidelines for use of rotavirus vaccine
11. Failure of live attenuated oral rotavirus vaccine
12. Comparison of reactogenicity and antigenicity of M37 rotavirus vaccine and rhesus-rotavirus-based quadrivalent vaccine
13. Reactogenicity and immunogeneicity of a high-titer rhesus rotavirus-based quadrivalent rotavirus vaccine
14. Challenges for rotavirus vaccines
15. Review of G and P typing results from a global collection of rotavirus strains: Implications for vaccine development
16. Evaluation of the efficacy of a low-passage bovine rotavirus (strain WC3) vaccine in children in Central Africa
17. Polymerase chain reaction amplification and typing of rotavirus nucleic acid from stool specimens
18. Human-rhesus reassortant rotavirus vaccines: Safety and immunogenicity in adults, infants, and children
19. A trail of an attenuated bovine rotavirus vaccine (RIT 4237) in Gambian children
20. Classification of rotavirus VP4 and VP7 serotypes
21. Serotypic characterization of rotaviruses derived from asymptomatic human neonatal infection
22. Construction of four double gene substitution human x bovine rotavirus reassortant vaccine candidates: Each bears two outer capsid human rotavirus genes, one encoding P serotype 1A and the other encoding G serotype 1,2,3, or 4 specificity
23. Determination of bovine rotavirus G and P serotypes by polymerase chain reaction
24. Rotaviruses
25. Antigenic relationships among five reovirus-like (RVL) agents by complement fixation (CF) and development of new substitute CF antigens for the human RVL agent of infantile gastroenteritis
26. Jennerian and modified Jennerian approach to vaccination against rotavirus diarrhea using a quadrivalent rhesus rotavirus (RRV) and human-RRV reassortant vaccine
27. The relative frequencies of G serotypes of rotaviruses recovered from hospitalized children with diarrhea: A 10-year survey (1987-1996) in Japan with a review of globally collected data
28. Comparison of immunoglobulin A (IgA), IgG, and IgM enzyme linked immunosorbent assays, plaque reduction neutralization assay and complement fixation in detecting seroresponses to rotavirus vaccine candidates
29. Efficacy of the Rhesus rotavirus-based quadrivalent vaccine in infants and young children in Venezuela
30. Phase I evaluation of coldadapted (CA) human rotavirus strain 75-82 (VP7:1) in adult volunteers
31. Trials of oral bovine and rhesus rotavirus vaccines in Finland: A historical account and present status
32. A comparative trial of rhesus monkey (RRV-1) and bovine (RIT 4237) oral rotavirus vaccines in young children
33. Development of rotavirus vaccines